GSK fleshes out growth plans as generics and Avandia drag on financials
This article was originally published in Scrip
Executive Summary
GlaxoSmithKlinesaw its share price decline by nearly 5% during trading on Wednesday after the company delivered lacklustre results for the first half and second quarter of the year, although it recovered to close down by 0.3% at £12.21.